First Patient Treated with Titan Pharmaceuticals’ Subdermal Implant for Parkinson’s Disease

(October 12, 2017) –  Titan Pharmaceuticals, Inc., a company developing proprietary therapeutics for the treatment of select chronic diseases utilizing its ProNeura™ long-term, continuous drug delivery technology, announced today that the first patient has been treated in a Phase 1/2 trial of the company’s ropinirole implant intended for the treatment of the signs and symptoms of idiopathic Parkinson’s disease. Read more…